102 related articles for article (PubMed ID: 15265836)
1. Genes harbor clues to addiction, recovery.
Hampton T
JAMA; 2004 Jul; 292(3):321-2. PubMed ID: 15265836
[No Abstract] [Full Text] [Related]
2. The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers.
Mitchell JM; Fields HL; White RL; Meadoff TM; Joslyn G; Rowbotham MC
J Clin Psychopharmacol; 2007 Feb; 27(1):112-5. PubMed ID: 17224736
[No Abstract] [Full Text] [Related]
3. The μ-opioid receptor and treatment response to naltrexone.
Thorsell A
Alcohol Alcohol; 2013; 48(4):402-8. PubMed ID: 23543091
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of alcoholism: a clinical neuroscience perspective.
Ray LA; Courtney KE; Bujarski S; Squeglia LM
Pharmacogenomics; 2012 Jan; 13(2):129-32. PubMed ID: 22256863
[No Abstract] [Full Text] [Related]
5. Study suggests gene may predict success of therapies for alcohol dependence.
Kuehn BM
JAMA; 2011 Mar; 305(10):984-5. PubMed ID: 21386072
[No Abstract] [Full Text] [Related]
6. Questionable efficacy for naltrexone in patients with Asp40.
Mattes JA
Arch Gen Psychiatry; 2009 Jul; 66(7):796; author reply 796-7. PubMed ID: 19581571
[No Abstract] [Full Text] [Related]
7. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
Ooteman W; Naassila M; Koeter MW; Verheul R; Schippers GM; Houchi H; Daoust M; van den Brink W
Addict Biol; 2009 Jul; 14(3):328-37. PubMed ID: 19523047
[TBL] [Abstract][Full Text] [Related]
8. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
Setiawan E; Pihl RO; Benkelfat C; Leyton M
Pharmacogenomics; 2012 Jul; 13(10):1161-72. PubMed ID: 22909206
[TBL] [Abstract][Full Text] [Related]
9. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
[TBL] [Abstract][Full Text] [Related]
10. Findings on alcohol dependence point to promising avenues for targeted therapies.
Kuehn BM
JAMA; 2009 Apr; 301(16):1643-5. PubMed ID: 19383946
[No Abstract] [Full Text] [Related]
11. Pharmacogenetic treatments for drug addiction: alcohol and opiates.
Haile CN; Kosten TA; Kosten TR
Am J Drug Alcohol Abuse; 2008; 34(4):355-81. PubMed ID: 18584566
[TBL] [Abstract][Full Text] [Related]
12. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.
Coller JK; Cahill S; Edmonds C; Farquharson AL; Longo M; Minniti R; Sullivan T; Somogyi AA; White JM
Pharmacogenet Genomics; 2011 Dec; 21(12):902-5. PubMed ID: 21946895
[TBL] [Abstract][Full Text] [Related]
13. Prospects for a genomic approach to the treatment of alcoholism.
O'Brien CP
Arch Gen Psychiatry; 2008 Feb; 65(2):132-3. PubMed ID: 18250250
[No Abstract] [Full Text] [Related]
14. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA; Hutchison KE
Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
[TBL] [Abstract][Full Text] [Related]
15. Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics.
Ray LA; Chin PF; Miotto K
CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):13-22. PubMed ID: 20201811
[TBL] [Abstract][Full Text] [Related]
16. The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review.
Ray LA; Barr CS; Blendy JA; Oslin D; Goldman D; Anton RF
Alcohol Clin Exp Res; 2012 Mar; 36(3):385-94. PubMed ID: 21895723
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial.
Schacht JP; Hoffman M; Chen BH; Anton RF
Pharmacogenomics J; 2022 Feb; 22(1):1-8. PubMed ID: 34381173
[TBL] [Abstract][Full Text] [Related]
18. Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus.
Barr CS; Chen SA; Schwandt ML; Lindell SG; Sun H; Suomi SJ; Heilig M
Biol Psychiatry; 2010 Jan; 67(1):78-80. PubMed ID: 19748082
[TBL] [Abstract][Full Text] [Related]
19. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.
Oroszi G; Anton RF; O'Malley S; Swift R; Pettinati H; Couper D; Yuan Q; Goldman D
Alcohol Clin Exp Res; 2009 Mar; 33(3):383-93. PubMed ID: 19053977
[TBL] [Abstract][Full Text] [Related]
20. Opioid pharmacogenetics of alcohol addiction.
Berrettini W
Cold Spring Harb Perspect Med; 2013 Jul; 3(7):. PubMed ID: 23729643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]